Dow Inc. — A Long-Term Business Owner's Research Report

Customers and how it gets paid. The company's revenue comes mainly from selling chemicals and materials to manufacturers and distributors. The annual report states clearly that product sales are typically contracted via order confirmations or purchase orders, mostly short-term contracts; control usually transfers at shipment, with payment terms generally 30-60 days. This means its revenue is not SaaS-style sticky subscription income but a steady yet unstable flow of industrial orders. Dow also has technology licensing and long-term supply contracts: as of year-end 2025, unsatisfied performance obligations tied to technology licensing were $617 million, to be recognized over the next five years; some long-term supply agreements have remaining terms of up to 18 years. This adds stability, but not enough scale to change the company's overall cyclical nature.

Stability and concentration. In 2025 the company disclosed plainly that no material portion of its sales depends on a single customer; sales are made mainly through its own sales force, with reliance on distributors in a few businesses. This is a good thing: Dow's risk lies not in customer concentration but in demand that is broad while margins are concentrated and exposed to commodity-chain spreads. If the stock market closed for five years, would I be willing to hold this business? The answer is: I could hold a small position, but it would be hard to hold a large one with confidence. You can understand what it sells, yet you cannot hold the same high certainty about its unit economics five years out as you can with Coca-Cola or Microsoft.

Industry and competitive landscape. This is not "the worst company in a bad industry," but it still sits closer to a mature, asset-heavy, strongly cyclical industry than a structurally high-return one. The main competitors Dow itself lists in the annual report span Chevron Phillips, ExxonMobil, INEOS, LyondellBasell, SABIC, Shell, Sinopec, BASF, Eastman, Arkema, Wacker, and Shin-Etsu, indicating it operates in a global, oligopolistic, yet still highly competitive market. Long-term industry demand exists — packaging, construction, automotive, electrical, electronics, and personal care will not disappear — but stable demand does not equal stable profit; the clearest proof is that company-wide net sales fell 7% in 2025, with prices under broad pressure across all three segments.

Long-term industry demand is broadly positive but easily disturbed by three forces: new supply, energy/feedstock prices, and regulatory/ESG pressure. In its risk factors, Dow lists feedstock and energy cost volatility, plastics-environment sentiment, trade policy, key customer/supplier relationships, and regulatory change as material risks; through 2025 and into early 2026, its public materials kept citing structurally high European costs, global supply-demand, and the Middle East conflict as profit headwinds. My inference: this is not an industry that will be overturned overnight by technology, but one that will be repeatedly reshaped by supply-demand, policy, and regional cost curves.

Moat assessment. Judging each of your ten moat types in turn, Dow's conclusions are roughly: brand advantage weak to medium; cost advantage medium; scale advantage medium; network effects almost none; switching costs low to medium; channel/customer synergy medium; patent/license/regulatory barriers medium to weak; data advantage weak; corporate culture/operating capability medium to strong; capital-allocation ability medium to weak. The evidence supporting this is that the company does have a low-cost feedstock position, global scale, world-class assets, and proprietary processes, plus a large patent portfolio — roughly 3,900 active U.S. patents and 25,800 active foreign patents at year-end 2025 — but historical returns have not shown the "high and stable" profile a strong-moat business should display.

Is the moat widening, stable, or narrowing? My judgment: modestly narrowing overall. In its integrated Americas assets and polyolefins chain, Dow's cost advantage and supply reliability still hold; but in Europe, in 2025 the company already announced the shutdown of three upstream assets to cope with structurally high costs, and does not expect to fully realize the roughly $200 million EBITDA uplift target until 2029. This shows it is not "widening a moat" but "repairing an eroded cost position." So for new entrants, replicating Dow's global asset network would take years and billions of dollars of capital; but for existing giant rivals, these capabilities are not impossible to replicate, so scale looks more like a barrier to entry than a wall that keeps excess returns durable.

Can Dow raise prices in an inflationary environment? The answer: yes, but it cannot consistently over-raise. In 2021 the company achieved record sales of $55 billion and $9.5 billion of Operating EBIT, showing strong price pass-through during tight supply-demand and rising costs; but profit fell quickly in 2022-2025, with Operating EBIT of just $422 million in 2025 and only $154 million in Q1 2026, indicating that this pass-through was largely a cyclical dividend rather than consumer-goods-style structural pricing power. Can the company stay profitable in a downturn? The answer: it can stay solvent and keep an investment-grade rating, but it cannot guarantee attractive profits.

Management and Capital Allocation

Dow's governance framework is broadly proper. The 2026 proxy statement shows that 11 of the 12 director nominees are independent, the company has an independent lead director, and executives and directors are prohibited from hedging or pledging company stock. This shows basic governance discipline is in place.

Is management honest, rational, and long-term oriented? My judgment: honesty medium-to-high, rationality medium, long-term orientation present but not strong enough to offset the industry's flaws. Three facts support this. First, in mid-2025 the company chose to halve the quarterly dividend, explaining clearly in the annual-report shareholder letter that this was to preserve financial flexibility; for a cyclical company, this is a painful but rational choice. Second, in 2024-2025 the company advanced the Diamond Infrastructure Solutions transaction, receiving roughly $3 billion in cash and hedging the downcycle's funding pressure. Third, in 2026 it launched Transform to Outperform, including the adjustment of about 4,500 roles, aimed at improving near-term EBITDA and efficiency. In other words, management has not papered over the situation but is playing defense.

But the capital-allocation record is not excellent. In 2025 the company did not repurchase stock; as of year-end 2025, the $3 billion buyback authorization granted in 2022 still had about $931 million unused. On the surface, this is "not spending recklessly" at low prices, which deserves credit; but conversely, the company repurchased $625 million in 2023 and another $500 million in 2024, only to hit a deeper trough in 2025 and be forced to cut the dividend. At minimum this shows that over the past two years the company has not demonstrated the outstanding countercyclical capital allocation of "buying back heavily when clearly undervalued and holding off when overvalued."

Management ownership and shareholder alignment are "medium," not "founder-level." The proxy statement shows that executives and directors beneficially own only about 0.5% in aggregate; CEO Jim Fitterling meets the 6x compensation ownership guideline and Karen Carter meets the 4x compensation guideline, but this reflects rule-based constraint more than a very high owner mindset. At the same time, the company's pay design ties annual bonus and long-term incentives to metrics such as Operating EBIT, Free Cash Flow, Operating ROC, cumulative cash flow from operations, and relative TSR, which is more reasonable than a pure EPS metric. The problem is that good metrics do not automatically equal good results: the company's operating return was negative 1% in 2025, and just 6%/6% in 2023-2024, showing no ability to channel capital toward high-return opportunities over the long run.

Worth special note: on July 1, 2026, Dow will undergo a leadership handover: Karen S. Carter will succeed as CEO and Jim Fitterling will become executive chairman. This is a planned succession rather than a crisis-driven reshuffle, but it adds a layer of execution uncertainty to a company already in a deep cycle and restructuring. For a prospective investor, this is not a disqualifier, but it does reduce the appeal of "buying heavily right now."

My overall score: management and capital allocation 3/5. I am willing to give Dow's management a "passing" grade, because it did not blow up the balance sheet at the cyclical trough and did not cling to defending an uncoverable dividend; but I will not give it an "excellent" grade, because capital returns over the past few years have been poor, and some assets even saw $690 million of goodwill impairment and $303 million of asset impairment in 2025, showing that the economic results of some earlier capital deployment were not ideal.

Financial Quality and Owner Earnings

Let me start with the most important sentence: Dow's problem is not "whether it can generate revenue" but "whether, after passing through a full cycle, it can leave behind free cash flow and capital returns that are thick enough and stable enough." The table below makes this clear.

• 2020 uses the continuing-operations basis from the 2020 annual report, which does not map one-to-one with the press-release basis of later annual reports. The 2020-2025 revenue, net income, Operating EBIT, and cash flow from operations in the table come from the company's annual reports / full-year results releases; LTM is my estimate from the full-year 2025 figure net of the 2026/2025 first-quarter difference.

Through a long-term business owner's lens, the implications of this table are not comfortable. 2021-2022 were high-prosperity, high-profit years, with revenue reaching $55-56.9 billion and Operating EBIT of $9.5 billion / $6.6 billion respectively; but 2023-2025 declined continuously, with Operating EBIT falling to $422 million in 2025, barely above breakeven. This says three things: first, Dow's profit is highly cyclical; second, peak years cannot be extrapolated into a stable norm; third, treating it as an "undervalued, stable cash cow" would be a directional error.

Now look at cash flow, capital expenditure, and returns. The proxy statement appendix discloses: Operating EBITDA for 2023-2025 of $5.389 billion, $5.482 billion, and $3.256 billion respectively; cash flow from operations of $5.164 billion, $2.903 billion, and $1.062 billion; capital expenditure of $2.356 billion, $2.940 billion, and $2.479 billion; free cash flow of $2.808 billion, negative $37 million, and negative $1.417 billion; cash-flow conversion of 96%, 53%, and 33%; and Operating ROC of 6%, 6%, and negative 1%. This is a strong chain of evidence: profit came down, cash-flow conversion deteriorated sharply, and capital returns showed none of the resilience of a moated business.

The latest quarter did not fundamentally reverse this. In Q1 2026 the company had revenue of $9.794 billion, Operating EBIT of $154 million, Operating EBITDA of $873 million, cash flow from operations of $1.124 billion, capital expenditure of $503 million, and free cash flow of $621 million. Cash flow looks markedly improved, but the company itself explains this mainly reflects a payment received from NOVA Chemicals and working-capital improvement; so I will not annualize the 1Q26 cash flow directly. More importantly, Q1 2026 also brought a material impact on the income statement and balance sheet from an accounting change tied to the Sadara project financing guarantee obligation, and under GAAP the company has suspended recognition of Sadara equity losses, because the carrying value of the related liability has reached the total of existing related obligations and commitments. For a long-term owner, this is not "bad news landing" but a reminder that this kind of JV/guarantee risk makes the correspondence between accounting profit and economic profit more complex.

On the balance sheet, Dow can still survive, but not comfortably for a conservative investor. As of March 31, 2026, the company had total debt of $18.135 billion, cash of $4.110 billion, marketable securities of $410 million, and net debt of $13.615 billion; net debt to capital was about 44.8%. On the same date, credit ratings were Fitch BBB/Stable, Moody's Baa3/Negative, and S&P BBB-/A-3 Negative. Using trailing-12-month adjusted Operating EBITDA, net debt/EBITDA is about 4.3x; using trailing-12-month Operating EBIT, interest coverage is under 0.5x, and even covered with EBITDA it is only about 3.7x. For a chemicals company in a deep cycle, I would not call this leverage a dangerous threshold, but it is by no means loose.

Working-capital signals are not especially easy either. At the end of Q1 2026, total inventory rose to $6.775 billion, above the $6.595 billion at year-end 2025; days of receivables/inventory/payables were 46 / 66 / 56 days respectively, versus roughly 42 / 61 / 59 days a year earlier. This shows working-capital tie-up has not clearly improved to a "high cash-efficiency" state. For an asset-heavy cyclical, such changes are not dangerous in themselves, but they remind you that as the cycle swings, Dow can easily absorb and release large amounts of cash through working capital.

On the shareholder-return record, Dow's dividend is not untouchable. In July 2025 the company announced a 50% cut to the quarterly dividend; actual 2025 payout was $2.10 per share, totaling $1.490 billion in distributions; but that year's cash flow from operations was only $1.062 billion and free cash flow was negative, showing the old dividend level was unsustainable. At the same time, the company did not repurchase shares in 2025; in 2023-2024 it repurchased $625 million and $500 million respectively. My read: dividends and buybacks both serve shareholder returns, but Dow's real priority is to protect the rating first, then flexibility, and distribution last. For a cyclical company that is not bad, but you cannot price it as a "stable-yield stock."

On accounting quality, I see no direct sign of financial fraud. The 2025 annual-report audit opinion was unqualified, and internal controls were effective. Cash flow from operations significantly exceeded net income in 2023-2024, also showing cash has not systematically lagged profit. The real issue is not "fraud" but a very noisy income statement: restructuring, impairments, NOVA litigation payouts, Sadara obligations, fair-value changes, and JV equity swings all distort single-year EPS. So when analyzing Dow, looking at P/E alone is basically meaningless; you must see through the cycle and look at cash flow, returns, and leverage.

Owner earnings analysis. Estimated on a Buffett-style owner-earnings basis, the "real distributable cash flow" for 2025 does not look good. Cash flow from operations in 2025 was $1.062 billion and total capital expenditure was $2.479 billion; the company has deferred the Fort Saskatchewan Path2Zero project, meaning the growth component of 2025 CapEx has fallen relative to the original plan; so treating 80%-90% of 2025 CapEx as maintenance capex is not aggressive. Under this conservative assumption, 2025 owner earnings are roughly in the range of negative $900 million to negative $1.1 billion.

But a single year is too affected by the cycle, so I prefer the 2023-2025 average. Three-year average cash flow from operations is about $3.04 billion; if I conservatively treat 80%-85% of average CapEx as maintenance capex, maintenance CapEx is about $2.07-2.20 billion, giving a conservative "mid-cycle owner earnings" of about $850 million to $1 billion. This means Dow's current equity valuation is roughly equivalent to 25-30x conservative owner earnings; for a materials company with an ordinary moat, heavy capital intensity, and extreme cyclicality, that is not cheap.

Valuation and Margin of Safety

First, a current valuation snapshot. At the latest price of $34.77, Dow's market cap is about $25.08 billion. Using Q1 2026 net debt of $13.615 billion, enterprise value is about $38.69 billion. Using a rough trailing-12-month adjusted Operating EBITDA of about $3.185 billion, EV/EBITDA is about 12.2x; using end-of-Q1 shareholders' equity of $16.763 billion, price-to-book is about 1.5x. Annualizing the current quarterly dividend of $0.35, the current dividend yield is about 4.0%. This valuation is not cheap — at least not cheap enough to reveal a large margin of safety at a glance.

It becomes clearer when you put Dow next to lower-risk opportunities. The U.S. Treasury homepage discloses that the 1-year Treasury par yield on May 28, 2026 was 3.80%. Dow's current annualized dividend yield of about 4.0% is only a narrow notch above the 1-year Treasury, and in 2025 Dow's dividend already proved it can be cut. This matters greatly for a balanced-to-conservative investor: if you take on strongly cyclical equity risk yet receive a cash yield close to the short-end Treasury, you can only pin your hopes on future profit recovery and valuation re-rating. That is not my favorite payoff structure.

Owner-Earnings Discount Method

Here is a three-scenario valuation I built on an "owner earnings" basis. Let me first state the assumptions clearly: [Assumption] I do not directly extrapolate 2025's negative owner earnings, because that is near a deep trough; nor do I directly annualize 1Q26, because that quarter was boosted by the NOVA payment and working-capital reflow. [Assumption] I adopt conservative-to-neutral mid-cycle owner-earnings starting points of $0.8 / 1.5 / 2.2 billion, corresponding to conservative, fair, and optimistic scenarios respectively. [Assumption] The discount rate uses 10% / 9% / 8.5%; the terminal growth rate uses 1.5% / 2.0% / 2.5%; the forecast horizon is a uniform 10 years. These assumptions are not facts, only a way to clarify "whether the current price is cheap." The factual basis supporting them is the cash flow, CapEx, and ROIC of 2023-2025 and the profit and restructuring status as of early 2026.

Roughly dividing by about 720 million shares of capital, this corresponds approximately to per share: conservative $15-22, fair $28-38, optimistic $45-60. So the current $34.77 sits roughly in the upper-middle of my "fair scenario range" and does not constitute an obvious discount. By conservative investing principles, I would want to see at least a 25%-30% discount to the "fair-value midpoint" before I would say "there is a margin of safety."

Relative Valuation Method

Relative valuation is very "hard to use" in this industry at the current moment, but it still offers one important piece of information: most peers' profits are likewise torn apart by the cycle right now. In the latest available market data, the trailing P/Es of Dow, LyondellBasell, Westlake, and Celanese are all negative, with only Eastman positive at about 22.1x. This shows that cross-sectional P/E comparison right now cannot tell you who is cheap, only that the entire materials-and-chemicals sector's current earnings basis is fragile. This is precisely one reason I am unwilling to give Dow a high score — if the whole industry is losing money or near losses, you are facing an industry structure rather than a single-stock mispricing.

The point of the table above is not to "pick the cheapest negative P/E" but to show that Dow does not currently display extreme undervaluation relative to peers; rather, the whole industry has become hard to judge by traditional multiples because of the cycle. For a conservative investor, this usually means continuing to wait rather than acting rashly.

Asset and Liquidation Value Method

Dow's book assets are not small, but I will not treat book net assets as a strong cushion. As of the end of Q1 2026, the company had total assets of about $59.78 billion and shareholders' equity of about $16.76 billion; it also had $18.135 billion of total debt, $4.542 billion of non-current pension and post-retirement benefit liabilities, $602 million of non-current asbestos-related liabilities, and even larger other non-current obligations. Such a balance sheet means: the book value is real, but the liquidation discount would also be very large. Chemical plants are highly specialized assets that often cannot fetch good prices in a downturn; layering on environmental, decommissioning, asbestos, and pension obligations, book net assets cannot simply be treated as a "floor price." So Dow's asset method supports "not an endangered company" rather than "obviously cheap assets."

After combining the three methods, my price conclusion is: Conservative intrinsic-value range: $15-22; fair intrinsic-value range: $28-38; optimistic intrinsic-value range: $45-60. Ideal buy range: $24-28; acceptable holding range: $28-38; clearly overvalued range: above $45. So my answer to "is it cheap enough now" is: not enough. The current price looks more like "already pricing in part of the recovery expectation," but it has not yet given long-term conservative investors a thick enough cushion for error.

Risks, Comparison, and Final Conclusion

The most important risk is not short-term volatility but permanent loss of capital. At Dow, the most important risks in order are: first, cyclical risk — global supply-demand imbalance, falling prices, and insufficient operating rates will repeatedly compress profit; second, leverage risk — investment grade still holds, but Baa3/BBB- is no longer loose, and if earnings stay weak for long, credit quality could keep deteriorating; third, Sadara and JV/guarantee risk — suspending equity-loss recognition in accounting does not mean the economic risk has vanished; fourth, European structural cost risk — if the European shutdowns and optimization fall short, regional capital will keep dragging on returns; fifth, regulatory and plastics-sentiment risk — the plastics circular economy, carbon policy, public sentiment, and trade policy could all change the demand structure and cost curve.

The strongest opposing view is actually compelling: Dow may not be a "cheap good company" at all, but simply "an ordinary cyclical at the trough." Bears would say that the high profits of 2021 are not the norm, and that the true mid-cycle ROIC is closer to the last three years' 6%, 6%, negative 1%; the company already took large goodwill and asset impairments in 2025, showing the true return on historical capital was lower than imagined; and even if the 2026 cost actions work and owner earnings recover to "decent but not exceptional," that still would not support today's valuation premium. If these judgments hold, then Dow is not a value stock but a cyclical on the edge of a value trap. I consider this opposing logic serious and worthy of respect.

What facts, if they appeared, should make me admit I was wrong? If you are bullish, you would at least need to see: the European shutdowns and Transform to Outperform significantly improving cash flow before 2027; Sadara-related obligations no longer deteriorating; Operating ROC stabilizing back above the high single digits; net debt/EBITDA falling clearly; and the dividend being robustly covered by cash flow from operations. Conversely, if you see another dividend cut, a further credit downgrade, expanded Sadara obligations, a failure of European asset optimization, or post-restructuring ROIC still below the cost of capital, then the investment thesis should be reassessed quickly.

Comparing Dow against other opportunities, my conclusion does not favor it. Versus more cycle-resilient companies in the industry, Eastman at least still keeps a positive trailing P/E, reflecting its stronger specialty profile; versus more directly comparable LyondellBasell, Westlake, and Celanese, Dow shows no clearly overwhelming valuation advantage. Versus the broad U.S. index represented by SPY, Dow's expected return is not clearly above the long-term equity cost of capital, yet it carries more concentrated cyclical and execution risk. Versus the risk-free yield of the 1-year U.S. Treasury at about 3.8%, Dow's current dividend yield of about 4.0% does not offer good enough risk compensation, because this dividend was already cut once in 2025. My judgment: buying it is not clearly better than buying the index, nor clearly better than patiently waiting for a better price.

Investment Checklist

The core meaning of this checklist is: Dow passes "understandable business" and "broadly rational management," but fails "moat, free-cash-flow stability, return on capital, and margin of safety." That is not enough to constitute a high-confidence long-term buy.

Final Investment Conclusion

[Final Rating] Watch

[One-Sentence Investment Thesis] Dow is an asset-heavy materials company that is understandable and can survive cycles but cannot easily compound; at today's price of about $35, there is not yet a thick enough long-term margin of safety.

[Core Bull Case]

• Low-cost North American feedstock, an integrated ethylene-to-polyethylene chain, global scale, and polyolefins leadership do give the company a relative cost advantage.

• Diversified customers and end-market demand spanning packaging, construction, consumer, electronics, and infrastructure, with no single-customer dependence.

• At the trough, management took rational actions such as protecting the rating, preserving cash, deferring large projects, divesting non-core assets, and cutting costs.

• If cyclical recovery in 2026-2028 combines with the European shutdowns and Transform to Outperform landing, the profit upside could be large.

[Core Bear Case]

• The business is easy to understand, but it is not "a good company in a good industry"; it is more like "an excellent operator in an ordinary industry."

• 2025 free cash flow was negative and the dividend was halved, showing cash flow is not stable at the trough.

• Operating ROC over the past three years was just 6%, 6%, negative 1%, showing none of the capital-return profile of a strong-moat business.

• Net debt/EBITDA is still high and the credit rating sits near the lower edge of investment grade; a longer cycle would harm shareholder returns.

• The current price is closer to a "fair-value range" than an "obviously undervalued range."

[Key Assumptions]

• The North American feedstock advantage will not be severely eroded.

• The European shutdowns and organizational restructuring can deliver clear cost benefits as planned.

• Sadara-related obligations do not keep deteriorating significantly.

• Mid-cycle owner earnings can recover to at least the $850 million-1.5 billion range.

[Fair Buy Price] I give an ideal buy range of $24-28, because that roughly corresponds to a 25%-30% margin of safety from the lower end to below the midpoint of my "fair intrinsic-value range"; $28-38 looks more like a range you can hold but should not add to aggressively; above $45 I would treat as clearly overvalued.

[Target Holding Period] If you buy, it suits only a 5-10-year-plus hold under a full-industry-cycle view; but this kind of hold is more like "moving with the cycle" than "compounding while you rest easy."

[Expected Annualized Return]

• Conservative scenario: 0%-3%.

• Neutral scenario: 5%-8%.

• Optimistic scenario: 10%-13%. These return estimates depend essentially on profit repair and owner-earnings recovery, not short-term valuation speculation.

[Maximum Loss Risk] From the current price, if the industry suffers long-term supply-demand imbalance, restructuring falls short, Sadara obligations keep eroding value, and the market re-prices the company down to my conservative intrinsic-value range, a 40%-60% permanent loss of capital is not unimaginable.

[Tracking Metrics] Going forward I will keep tracking: Operating EBIT, Operating EBITDA, free cash flow, cash-flow conversion, Operating ROC, net debt/EBITDA, dividend coverage, volume and price in the packaging and polyethylene chain, European shutdown progress, Sadara guarantee obligations, and credit rating and outlook.

[Signals That Trigger Reassessment] If there is another dividend cut, a further credit-rating deterioration, an expansion of Sadara-related burdens, a failure of European optimization, post-restructuring ROIC still clearly below the cost of capital, or free cash flow still unable to turn stably positive during the recovery, I will revisit the entire investment thesis.

[Final Recommendation] If your goal is to find a name you can "hold with confidence for 10-plus years, like buying a whole company," I would classify Dow as worth researching and worth waiting for, but not worth rushing to buy yet. It is not a bad company, but it is also not so excellent that you can ignore price; it is not necessarily a trap, but it is by no means already significantly mispriced. For your balanced-to-conservative risk appetite, I lean toward putting Dow on the watch list, waiting for one of two things to appear: either a lower price, or a more verifiable recovery in earnings and cash flow. Until either happens, Dow is more of a cyclical bet than a high-certainty long-term ownership investment.

Open Questions and Limitations. This report prioritized the 2025 10-K, the 2026 Q1 10-Q, the 2026 proxy, official results releases, and current market data; but rebuilding EV/EBITDA, P/FCF, and ROIC for every comparable company would require a separate round of filing-by-filing review, and so far only Dow's own high-confidence estimates and peer headline P/E and market-cap comparisons have been completed. Another key limitation is that maintenance capital expenditure cannot be read directly from the statements, so all owner-earnings and DCF figures should be treated as deliberately conservative estimates rather than precise values.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.